Background: The process of obtaining approval for hepatitis C virus (HCV) treatment may be time consuming and complicated due to prior authorizations and the need to appeal denials. Pharmacists are poised to play a critical role in the acquisition and management of oral direct acting antivirals (DAAs) for the treatment of HCV infection; however, the time expended in this activity requires assessment. Objective: The objective of this study was to assess time expenditures by pharmacists to acquire DAAs for HCV therapy. Methods: Patients were enrolled in the Northwestern University Viral Hepatitis Registry, a prospective, observational cohort of ambulatory, adult patients living with human immunodeficiency virus (HIV) coinfected with chronic hepatitis B and/or C virus, and recruited since 2013 from the Infectious Disease Center at Northwestern Memorial Hospital, Chicago, IL. Patients were included in the current study if they were referred to the pharmacist for HCV DAA acquisition, drug-drug interaction management, and adherence counseling between February 1, 2014, and April 30, 2015. Patient demographics, virus-specific characteristics, and time required to secure HCV DAA treatment, counsel patients, and follow-up therapy were collected. Results: Among 54 HIV/HCV coinfected patients referred for treatment, all eventually received approval for DAA therapy. However, 87% (n = 47) required prior authorization. Pharmacists dedicated 2.1 hours/patient (interquartile range 1.5-2.8 hours; range 0.75-6.5 hours) to manage DAA therapy. Conclusion: Successful acquisition of HCV DAA therapy relied heavily on pharmacist effort, reflecting the vital role that pharmacists play in this process. Dedicated resources for medication access should be considered to ensure timely DAA acquisition.
Introduction
Despite strong recommendations to treat patients with chronic hepatitis C (HCV) infection who are coinfected with the human immunodeficiency virus-1 (HIV) at earlier stages of fibrosis (Metavir stage F0 or F1), many patients are still unable to access HCV therapy because of third party payer rejections. [1] [2] [3] Due to high costs of direct acting antiviral (DAA) therapy, most third party payers restrict access to these medications by requiring prior authorization (PA) with stringent guidelines for approval.
1-3 While these restrictions may have lessened and costs have decreased over time, patients are still denied access to DAAs. [4] [5] [6] In a busy clinical environment, health care providers may find difficulty in navigating the PA process and/or lack resources to pursue HCV DAAs for their patients. 7 Pharmacists play a critical role in the acquisition of treatment for HCV infection. 8, 9 Pharmacists increase the likelihood of patients achieving an optimal response to HCV therapy by providing patient education, adherence counseling, addressing patient concerns regarding treatment, and managing drugdrug interactions.
1, [8] [9] [10] However, the process of obtaining approval for HCV treatment may be time consuming due to
the need for prior authorization and potential appeal for third party payer denials. The objective of this study was to assess time expenditures by pharmacists to acquire DAAs for HCV therapy.
Methods
The Northwestern University (NU) Viral Hepatitis Registry is a prospective, observational cohort study of ambulatory, adult patients living with HIV coinfected with chronic hepatitis B and/or C virus, and recruited since 2013 from the Infectious Disease (ID) Center (IDC) at Northwestern Memorial Hospital, Chicago, IL. Within the IDC, a multidisciplinary team of ID physicians, a hepatologist, nurses, social workers, and pharmacists, provide clinical care to HIV/HCV coinfected patients. Patients are insured through public or private programs. The IDC is not funded by the Ryan White HIV/AIDS Program. For this study, patients were included if they were referred to the pharmacist for HCV DAA acquisition, drug-drug interaction management, and adherence counseling between February 1, 2014, and April 30, 2015, as part of the standard of care protocol. Pharmacists were responsible for the entire PA process. This study was reviewed and approved by the institutional review boards at NU and Midwestern University.
As the standard of care at the IDC, the pharmacist plays an active role in determining the best treatment option, reviewing the patient's maintenance medications for drugdrug interactions with DAA therapy, initiating the PA process, and following-up until medications are able to be obtained. Pharmacists appeal denied PAs as needed and also seek therapy through patient assistance programs. Each patient receives counseling regarding medication, laboratory monitoring, and the HCV disease state. Laboratory results are also monitored and medications (eg, ribavirin) adjusted as appropriate after consultation with the prescribing physician. The pharmacists intervene when necessary to manage adverse events and provide refill reminder calls.
Patient demographics, virus-specific characteristics, information regarding PA and appeal requirements, and initial third party payer denial of HCV DAA prescription payment was collected. Time requirements to complete PAs, appeals for third party payer denials, counseling, and followup consults were also collected. To standardize the analysis, the time for one PA form was defined as 0.5 hours and 1 hour for appeals. This time included acquiring the correct PA forms, completion of initial PA forms or for writing appeals, transmission of documentation, assuring third party payer receipt, and follow-up on status of PA forms or appeals. Time for baseline counseling and patient assessment was 0.5 hours and 0.25 hours for any follow-up consults. 11 Descriptive statistics were compiled using Intercooled Stata, version 13 (Statacorp, College Station, TX).
Results
Fifty-four patients were referred for pharmacist consultation for HCV DAA acquisition and management; all patients were eventually approved for treatment. One patient was referred twice and approved for retreatment (both encounters were included in the analyses). Study participants were mostly male (n = 44, 82%) and Caucasian (n = 28, 54%), with a median age of 54 years (interquartile range [IQR] 46-60). The predominant HCV genotype was 1a (66.7%, n = 36) followed by genotype 1b (25.9%, n = 14), genotype 2 (5.6%, n = 3), and genotype 3 (1.9%, n = 1). The median baseline log HCV RNA was 6.23 IU/mL (IQR 5.86-6.57), and cirrhosis was present in 59% (n = 32) of patients. HIV RNA level was undetectable (<20 IU/mL) prior to HCV treatment in 98.1% (n = 53) of patients, and median CD4 T-lymphocyte count was 448 cells/mm 3 (IQR 284-621). Seventy-two percent (n = 39) of patients were treated with sofosbuvir (SOF)/simeprevir (SMV), 11% (n = 6) SOF/ribavirin, and 17% (n = 9) ledipasvir/SOF. Baseline HIV antiretroviral regimens were protease inhibitor based (31.4%, n = 17), non-nucleoside reverse transcriptase inhibitor based (31.4%, n = 17), integrase strand transfer inhibitor based (35.2%, n = 19), and nucleoside reverse transcriptase inhibitor only (1.9%, n = 1).
Among patients referred for DAA therapy, 87% (n = 47) required a PA (median 2 PA forms/patient; IQR 1-2 PA forms) involving 1 hour of pharmacist time per patient (range 0.5-1 hour; Table 1 ). The median time to DAA approval after PA form submission was 5 days (IQR 2-16.5 days, range 1-167 days). Initial HCV therapy submission for 29.6% (n = 16) of patients was denied and required appeal. One hour of pharmacist time per patient (range 1-3 hours) to appeal denied PAs was required. The median pharmacist time required for PAs, appeals, counseling, and follow-up was 2.1 hours/patient (IQR 1.5-2.8 hours, range 0.75-6.5 hours). Common reasons for pharmacist consults included management of adverse effects and issues involving receipt of medication from mail order pharmacies. Each patient received a median of 3 pharmacy consults (IQR 3-5 consults, range 1-9 consults) with 0.5 hours (IQR 0.25-1 hours, range 0-1.75 hours) median time needed for consults after initial counseling.
Discussion
Prior authorization was required for approximately 90% of HIV/HCV coinfected patients treated with DAA therapy.
Pharmacists spent approximately a median of 2 hours (up to 6.5 hours) per patient. The HCV medication access process requires dedicated interactions with third party payers and careful clinical care team coordination. This time requirement for interactions with third party payers could have been spent on other clinical medication management activities such as assessing adverse events or drug-drug interactions. Previously reported sustained virologic response at 12 weeks (SVR12) for this cohort exceeded 90%. 12 Clinical pharmacists possess the expertise and the ability to provide the critical support needed for HCV medication acquisition in multiple ways, including assembly of required clinical and third party payer information and evaluating the need for maintenance medication adjustments to avoid drugdrug interactions. 13 In an era where multiple DAA first-line treatment options exist in national guidelines for HCV therapy, pharmacists can provide clinically useful information in support of the need for specific HCV drug treatment combinations tailored to individual patient needs.
1 It may also be prudent for third party payers to implement a different approval process for patients coinfected with HIV/HCV since guideline recommendations for treatment in this patient group are clear.
1
At the IDC, pharmacist involvement led to a more efficient process compared to a prior published report citing a 77-day period before HCV DAA approval in a transplant population versus a median time to HCV drug approval of 5 days.
14 A survey of North American ID physicians identified a lack of clinical support in successfully accessing DAA therapy as a limiting factor in initiating HCV treatment initiation; several clinicians who expressed a willingness to manage patients with HCV were in need of supplemental clinical resources to do so. 7 It has been shown that delay of HCV therapy may result in progression of liver disease. 15 While the delay reported in the literature is 1 year, if HCV DAA treatment cannot be secured due to third party payer or other issues, patients may need to defer therapy until such time that it can be requested repeatedly. In this study, all patients were able to initiate DAA treatment; therefore, no patients needed to defer therapy.
Limitations of this study should be considered. The exact amount of time spent on medication access was not prospectively recorded. However, an approximate time required to complete each task was chosen to standardize across patients. This method likely underestimates the true amount of time needed for each task, further underscoring the need to consider personnel effort needed to achieve medication access. While the overall ease of obtaining DAA therapy for HCV is improving in the United States for access to HCV therapy, many of the same issues reported herein are still relevant for clinicians at the IDC. 4 
Conclusion
In this study, pharmacist dedicated time required to navigate the process of HCV DAA acquisition was considerable and essential, including time for patient education and drugdrug interaction management. This time could have been spent on other medication management activities. Pharmacist-based resource requirements should be considered in the overall personnel assessment of HCV therapy in order to access such treatment in a timely manner.
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